Immunosuppression and monitoring of rejection in hand transplantation

Techniques in Hand and Upper Extremity Surgery

Volumn 17, Issue 4, 2013, Pages 208-214

  Schneeberger, Stefan ^a,b   Khalifian, Saami ^a   Brandacher, Gerald ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Hand transplant; Immune regulation; Immunomodulation; Immunosuppression; Monitoring; Monotherapy; Rejection; Tolerance; Vascularized composite allotransplantation

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; GRAFT REJECTION; HAND TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; TRANSPLANTATION TOLERANCE;

CLINICAL PROTOCOLS; GRAFT REJECTION; HAND TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; TRANSPLANTATION TOLERANCE;

EID: 84890804690     PISSN: 10893393     EISSN: 15316572     Source Type: Journal    
DOI: 10.1097/BTH.0000000000000019     Document Type: Article

References (125)

1. Guild WR, Harrison JH, Merrill JP, et al. Successful homotransplantation of the kidney in an identical twin. Trans Am Clin Climatol Assoc. 1955;67:167-173
2. Merrill JP, Murray JE, Takacs FJ, et al. Successful transplantation of kidney from a human cadaver. JAMA. 1963;185:347-353
3. Carrel A. Landmark article, Nov 14, 1908: results of the transplantation of blood vessels, organs and limbs. By Alexis Carrel. JAMA. 1983;250:944-953
4. Lexer E. Substitution of whole or half joints from freshly amputated extremities by free plastic operation. Surg Gynecol Obstet. 1908;6: 601-609
5. Gilbert R. Transplant is successful with a cadaver forearm. Med Trib Med News. 1964;5:20-22
6. Gilbert R. Hand transplanted from cadaver is reamputated. Med Trib Med News. 1964;5:23-25
7. Brown JB, McDowell F. Epithelial healing and the transplantation of skin. Ann Surg. 1942;115:1166-1181
8. Gibson T, Medawar PB. The fate of skin homografts in man. J Anat. 1943;77(pt 4):299-310, 294
9. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612
10. Rosenthal JT, Hakala TR, Iwatsuki S, et al. Cadaveric renal transplantation under cyclosporinesteroid therapy. Surg Gynecol Obstet. 1983;157: 309-315
11. Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg. 1991;87:401-411
12. Jones JW Jr, Ustuner ET, Zdichavsky M, et al. Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. Surgery. 1999;126:384-388
13. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet. 1999;353:1315-1320
14. Kanitakis J, Jullien D, Petruzzo P, et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation. 2003;76:688-693
15. Jones JW, Gruber SA, Barker JH, et al. Successful hand transplantation. One-year follow-up. Louisville Hand Transplant Team. N Engl J Med. 2000;343:468-473
16. Pei G, Gu L, Yu L. A preliminary report of two cases of human hand allograft. Zhonghua Yi Xue Za Zhi. 2000;80:417-421
17. Margreiter R, Brandacher G, Ninkovic M, et al. A double-hand transplant can be worth the effort! Transplantation. 2002;74:85-90
18. Petruzzo P, Lanzetta M, Dubernard JM, et al. The international registry on hand and composite tissue transplantation. Transplantation. 2010;90:1590-1594
19. Hettiaratchy S, Melendy E, Randolph MA, et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation. 2004;77:514-521
20. Mathes DW, Randolph MA, Solari MG, et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation. 2003; 75:25-31
21. Tung TH, Mackinnon SE, Mohanakumar T. Combined treatment with CD40 costimulation blockade, T-cell depletion, low-dose irradiation, and donor bone marrow transfusion in limb allograft survival. Ann Plast Surg. 2005;55:512-518
22. Gaspari AA, Katz SI. Induction and functional characterization of class II MHC (Ia) antigens on murine keratinocytes. J Immunol. 1988; 140:2956-2963
23. Sugita K, Kabashima K, Atarashi K, et al. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clin Exp Immunol. 2007;147: 176-183
24. Uchi H, Terao H, Koga T, et al. Cytokines and chemokines in the epidermis. J Dermatol Sci. 2000;24(suppl 1):S29-S38
25. Hautz T, Zelger B, Grahammer J, et al. Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. Am J Transplant. 2010;10:1200-1209
26. Schneeberger S, Gorantla VS, Hautz T, et al. Immunosuppression and rejection in human hand transplantation. Transplant Proc. 2009;41: 472-475
27. Unadkat JV, Schneeberger S, Horibe EH, et al. Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. Am J Transplant. 2010; 10:251-261
28. Schneeberger S, Kreczy A, Brandacher G, et al. Steroid- and ATGresistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant. 2004;4:1372-1374
29. Schneeberger S, Ninkovic M, Gabl M, et al. First forearm transplantation: outcome at 3 years. Am J Transplant. 2007;7:1753-1762
30. Schneeberger S, Ninkovic M, Piza-Katzer H, et al. Status 5 years after bilateral hand transplantation. Am J Transplant. 2006;6:834-841
31. Schuind F, Van Holder C, Mouraux D, et al. The first Belgian hand transplantation-37 month term results. J Hand SurgBr. 2006;31:371-376
32. Schneeberger S, Gorantla VS, van Riet RP, et al. Atypical acute rejection after hand transplantation. Am J Transplant. 2008;8:688-696
33. Cendales LC, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant. 2008;8:1396-1400
34. Hautz T, Zelger B, Brandacher G, et al. Histopathologic characterization of mild rejection (grade I) in skin biopsies of human hand allografts. Transpl Int. 2012;25:56-63
35. Kanitakis J, McGregor B, Badet L, et al. Absence of c4d deposition in human composite tissue (hands and face) allograft biopsies: an immunoperoxidase study. Transplantation. 2007;84:265-267
36. Landin L, Cavadas PC, Ibanez J, et al. CD3 + -mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. Transplantation. 2009; 87:776-781
37. Wu S, Xu H, Chen B, et al. Sensitized recipients exhibit accelerated but not hyperacute rejection of vascularized composite tissue allografts. Transplantation. 2011;92:627-633
38. Diaz-Siso JR, Bueno EM, Sisk GC, et al. Vascularized composite tissue allotransplantation-state of the art. Clin Transplant. 2013;27: 330-337
39. Petruzzo P, Kanitakis J, Badet L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant. 2011;11:808-816
40. Kaufman CL, Blair B, Murphy E, et al. A new option for amputees: transplantation of the hand. J Rehabil Res Dev. 2009;46:395-404
41. Kaufman CL, Ouseph R, Blair B, et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant. 2012;12:1004-1016
42. Gander B, Brown CS, Vasilic D, et al. Composite tissue allotransplantation of the hand and face: a new frontier in transplant and reconstructive surgery. Transpl Int. 2006;19:868-880
43. Hautz T, Engelhardt TO, Weissenbacher A, et al. World experience after more than a decade of clinical hand transplantation: update on the Innsbruck program. Hand Clin. 2011;27:423-431, viii
44. Schneeberger S, Landin L, Jableki J, et al. Achievements and challenges in composite tissue allotransplantation. Transpl Int. 2011; 24:760-769
45. Hautz T, Brandacher G, Zelger B, et al. Immunologic aspects and rejection in solid organ versus reconstructive transplantation. Transplant Proc. 2010;42:3347-3353
46. Jindal RM, Das NP, Neff RT, et al. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database. Am J Nephrol. 2009;29:501-508
47. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant. 2005;5:2539-2548
48. Patlolla V, Zhong X, Reed GW, et al. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant. 2007;7:1832-1842
49. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005;200:505-515; quiz A559-561
50. Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation. 2009;87:1520-1529
51. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387-1394
52. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128:260-270
53. Kapic E, Becic F, Kusturica J. Basiliximab mechanism of action and pharmacological properties. Med Arh. 2004;58:373-376
54. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17:584-591
55. Canan S, Asim OM, Okan B, et al. Anatomic variations of the infraorbital foramen. Ann Plast Surg. 1999;43:613-617
56. Aziz SR, Marchena JM, Puran A. Anatomic characteristics of the infraorbital foramen: a cadaver study. J Oral Maxillofac Surg. 2000; 58:992-996
57. Hu KS, Kwak HH, Song WC, et al. Branching patterns of the infraorbital nerve and topography within the infraorbital space. J Craniofac Surg. 2006;17:1111-1115
58. Hwang K, Nam YS, Choi HG, et al. Cutaneous innervation of lower eyelid. J Craniofac Surg. 2008;19:1675-1677
59. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340
60. Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation. 2009;87:795-802
61. Ravindra KV, Ildstad ST. Immunosuppressive protocols and immunological challenges related to hand transplantation. Hand Clin. 2011;27:467-479, ix
62. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 1976;84:304-315
63. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol. 2008;19:1411-1418
64. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506-1514
65. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005;16:496-506
66. Chelmonski A, Jablecki J, Szajerka T. Insidious course of cytomegalovirus infection in hand transplant recipient: case report, diagnostics, and treatment. Transplant Proc. 2011;43:2827-2830
67. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant. 2007;21:149-158
68. Grossi P, Minoli L, Percivalle E, et al. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation. 1995;59:847-851
69. Ho M. Advances in understanding cytomegalovirus infection after transplantation. Transplant Proc. 1994;26(suppl 1):7-11
70. Bonatti H, Brandacher G, Margreiter R, et al. Infectious complications in three double hand recipients: experience from a single center. Transplant Proc. 2009;41:517-520
71. Murray JE, Gleason R, Bartholomay A. Third report of the human kidney transplant registry. Transplantation. 1965;3:294-302
72. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823-2831
73. Landin L, Cavadas PC, Ibanez J, et al. Malignant skin tumor in a composite tissue (bilateral hand) allograft recipient. Plast Reconstr Surg. 2010;125:20e-21e
74. Gruessner RW, Kandaswamy R, Humar A, et al. Calcineurin inhibitorand steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation. 2005;79:1184-1189
75. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358:353-361
76. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004;78:966-971
77. Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant. 2008;8:1480-1485
78. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358:362-368
79. Shapiro R, Ellis D, Tan HP, et al. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J Transplant. 2007;7:2736-2738
80. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502-1510
81. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2006;6:2409-2417
82. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one- and twoyear outcomes. Transplantation. 2006;82:1621-1624
83. Tryphonopoulos P, Madariaga JR, Kato T, et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc. 2005;37:1203-1204
84. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation. 2003;75:1512-1517
85. Brandacher G, Lee WP, Schneeberger S. Minimizing immunosuppression in hand transplantation. Expert Rev Clin Immunol. 2012;8:673-683; quiz 684
86. Brandacher G, Gorantla VG, Schneeberger S, et al. Hand/forearm transplantation using a novel cell-based immunomodulatory protocol-experience with five patients. Am J Transplant. 2011;11:190
87. Schneeberger S, Wachtman G, Gorantla VS, et al. Utilization of bone marrow cells for immunomodulation in transplantation. Am J Transplant. 2010;10(suppl. 4):116
88. Siemionow M, Nasir S. Impact of donor bone marrow on survival of composite tissue allografts. Ann Plast Surg. 2008;60:455-462
89. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg. 2013;257:345-351
90. Granger DK, Briedenbach WC, Pidwell DJ, et al. Lack of donor hyporesponsiveness and donor chimerism after clinical transplantation of the hand. Transplantation. 2002;74:1624-1630
91. Mirowitz SA. Hematopoietic bone marrow within the proximal humeral epiphysis in normal adults: investigation with MR imaging. Radiology. 1993;188:689-693
92. Taieb A, Clavijo-Alvarez JA, Hamad GG, et al. Immunologic approaches to composite tissue allograft. J Hand Surg. 2007;32:1072-1085
93. Devauchelle B, Badet L, Lengele B, et al. First human face allograft: early report. Lancet. 2006;368:203-209
94. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation. 2001;71:827-835
95. Ravindra KV, Wu S, Bozulic L, et al. Composite tissue transplantation: a rapidly advancing field. Transplant Proc. 2008;40:1237-1248
96. Starzl TE. Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med. 2008;358:407-411
97. Starzl TE, Demetris AJ, Trucco M, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (Baltimore, MD). 1993;17:1127-1152
98. Foster RD, Fan L, Neipp M, et al. Donor-specific tolerance induction in composite tissue allografts. Am J Surg. 1998;176:418-421
99. Pilat N, Hock K, Wekerle T. Mixed chimerism through donor bone marrow transplantation: a tolerogenic cell therapy for application in organ transplantation. Curr Opin Organ Transplant. 2012;17:63-70
100. Prabhune KA, Gorantla VS, Maldonado C, et al. Mixed allogeneic chimerism and tolerance to composite tissue allografts. Microsurgery. 2000;20:441-447
101. Fehr T, Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int. 2008;21:1118-1135
102. Klimczak A, Unal S, Jankowska A, et al. Donor-origin cell engraftment after intraosseous or intravenous bone marrow transplantation in a rat model. Bone Marrow Transplant. 2007;40:373-380
103. Orlando G, Hematti P, Stratta RJ, et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg. 2010;252:915-928
104. Pilat N, Wekerle T. Transplantation tolerance through mixed chimerism. Nat Rev Nephrol. 2010;6:594-605
105. Sykes M. Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials. Transplantation. 2009;87:309-316
106. Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med. 2001;52:353-370
107. Ramsamooj R, Llull R, Black KS, et al. Composite tissue allografts in rats: IV. Graft-versus-host disease in recipients of vascularized bone marrow transplants. Plast Reconstr Surg. 1999;104:1365-1371
108. Burke GW, Ricordi C, Karatzas T, et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplant recipients: a preliminary study. Transplant Proc. 1995;27:3121-3122
109. Burke GW, Ricordi C, Karatzas T, et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: evidence for augmentation of chimerism. Transplant Proc. 1997;29:1207-1208
110. Delis S, Ciancio G, Burke GW 3rd, et al. Donor bone marrow transplantation: chimerism and tolerance. Transpl Immunol. 2004;13:105-115
111. Murase N, Ye Q, Nalesnik MA, et al. Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation. 2000;70:1632-1641
112. Rao AS, Fontes P, Iyengar A, et al. Perioperative donor bone marrow infusion in recipients of organ allografts. Transplant Proc. 1997;29:2192-2193
113. Li XC, Turka LA. An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol. 2010;6:577-583
114. Matta BM, Castellaneta A, Thomson AW. Tolerogenic plasmacytoid DC. Eur J Immunol. 2010;40:2667-2676
115. Pilat N, Wekerle T. Mechanistic and therapeutic role of regulatory T cells in tolerance through mixed chimerism. Curr Opin Organ Transplant. 2010;15:725-730
116. Silk KM, Fairchild PJ. Harnessing dendritic cells for the induction of transplantation tolerance. Curr Opin Organ Transplant. 2009;14:344-350
117. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7:610-621
118. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. Semin Immunol. 2011;23:252-263
119. Foster RD, Ascher NL, McCalmont TH, et al. Mixed allogeneic chimerism as a reliable model for composite tissue allograft tolerance induction across major and minor histocompatibility barriers. Transplantation. 2001;72:791-797
120. Issa F, Hester J, Goto R, et al. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation. 2010;90:1321-1327
121. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5: 443-453
122. Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol. 2011;23:293-303
123. Siemionow M, Klimczak A, Unal S, et al. Hematopoietic stem cell engraftment and seeding permits multi-lymphoid chimerism in vascularized bone marrow transplants. Am J Transplant. 2008;8:1163-1176
124. Siemionow MZ, Izycki DM, Zielinski M. Donor-specific tolerance in fully major histocompatibility major histocompatibility complexmismatched limb allograft transplants under an anti-alphabeta T-cell receptor monoclonal antibody and cyclosporine A protocol. Transplantation. 2003;76:1662-1668.
125. Mathes DW, Hwang B, Graves SS, et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation. 2011;92:1301-1308